Quick Facts

• GLP-1 drugs reduced addiction risk by 15-20% across multiple substances in study of 606,000 veterans
• Patients with existing addictions saw 50% lower death risk and 39% lower overdose risk
• Multiple clinical trials now testing GLP-1s specifically for addiction treatment

GLP-1 drugs like Ozempic and Wegovy significantly reduce the risk of developing substance use disorders, according to a major study published in The BMJ medical journal.

Researchers analyzed electronic health records of more than 606,000 U.S. veterans with type 2 diabetes over three years. Veterans taking GLP-1 medications showed 18% reduced risk for alcohol disorders, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids.

The study found seven fewer new substance use disorder diagnoses per 1,000 GLP-1 users over three years compared to other diabetes medications.

For patients with existing addictions, the benefits proved even more dramatic. GLP-1 users experienced 31% lower emergency department visits, 26% fewer hospitalizations, 25% reduced suicidal thoughts, 39% lower overdose risk, and 50% lower death risk.

Brain Mechanism Revealed

Lead researcher Dr. Ziyad Al-Aly explained that patients report unexpected changes after starting GLP-1s. “Dr. So-and-so started me on Ozempic for diabetes or for weight loss, and all of a sudden, I don’t care for alcohol anymore, or I stopped smoking,” he noted.

The drugs work by reducing dopamine in the brain’s mesolimbic system, which controls reward signaling and motivation. This same system gets hijacked by addiction across all substances.

“People taking these drugs for obesity often describe a quieting of ‘food noise,’” Al-Aly said. “What our study suggests is something broader: GLP-1 drugs may also quiet what I call ‘drug noise,’ the relentless craving that drives addiction.”

Treatment Breakthrough Potential

The findings represent a major shift in addiction medicine. Current treatments typically target single substances – nicotine patches for smoking or naltrexone for alcohol – but no medication works across all addictive substances.

Dr. Anna Lembke from Stanford University called the research significant. “We haven’t really had a new tool in our toolbox from a pharmacotherapy perspective to treat addiction in a long time,” she said.

Nearly 50 million Americans have substance use disorders, yet only 3% of people with alcohol use disorder ever receive effective medication.

Clinical Trials Underway

Multiple clinical trials are testing GLP-1 drugs specifically for addiction treatment, with results expected over the next few years. The National Institute on Drug Abuse is evaluating semaglutide for alcohol reduction.

Dr. Lorenzo Leggio from the National Institutes of Health expressed optimism. “We have a lot of hope that these medications, if proven effective via controlled trials, may be helpful for multiple addictions,” he said.

The study has limitations as an observational analysis of mostly older, white male veterans. Researchers emphasize the findings don’t justify prescribing GLP-1s for addiction without randomized controlled trial evidence.

Read more: GLP-1 drugs like Ozempic can curb addiction risk, study finds